A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


August 2, 2011

Counseling, Drug Treatment Can Increase Hep C Treatment Eligibility

A combination of counseling and case management can help people living with hepatitis C virus (HCV) and psychiatric or substance use disorders to qualify for therapy to combat the infection, according to research reported in the July 2011 issue of The American Journal of Gastroenterology.  

Psychiatric illness and substance abuse are common among people living with HCV. HCV treatment—including clinical trial enrollment—is often withheld from people facing these challenges, because of concerns about worsening mental health, increasing drug or alcohol use and reducing adherence. But many people who have been considered ineligible for HCV treatment can become good candidates.

Donna Evon, PhD, from the University of North Carolina School of Medicine at Chapel Hill and her colleagues compared two approaches to increase HCV treatment eligibility in a clinical trial. The 101 study participants were originally considered ineligible for HCV treatment due to mental illness (35 percent), substance use disorders (alcohol 31 percent; drugs, 9 percent) or more than one of these conditions (26 percent).

At the beginning of the study, each participant was evaluated by a clinician who assessed HCV treatment eligibility. People who were ineligible received a thorough explanation of the reason for treatment deferral and then were given verbal and written recommendations to increase eligibility. At three, six and nine months, all study participants were re-evaluated.

About half the participants were assigned to an intervention group. They were contacted on a monthly basis, by phone or in person, and received individualized counseling, along with referrals to mental health and substance abuse treatment programs.

After nine months, participants in the intervention group were more than twice as likely to become eligible for HCV treatment than those assigned to standard medical re-evaluation (42 percent versus 18 percent). Overall, 30 participants became eligible for HCV treatment (21 from the intervention group, and nine from the standard re-evaluation group).  

A total of 19 people (12 from the intervention group; seven from the standard re-evaluation group) went on to begin HCV treatment in the study. The other eligible participants delayed treatment for various reasons, such as personal decisions, job-related or medical issues or because they were waiting for HCV protease inhibitors to become available; two were lost to follow-up, and two resumed drug or alcohol use.

Treatment for hepatitis C has become more effective; more than 70 percent of people with genotypes 1, 2 and 3 can be cured—if they are considered eligible for treatment. The authors noted that people rarely become eligible for HCV treatment after an initial deferral for mental illness or substance use disorders, although these conditions are usually manageable. This study is the first clinical trial demonstrating that a multidisciplinary intervention can greatly increase hepatitis C treatment eligibility.

Search: hepatitis, treatment, drugs, alcohol, depression, mental illness, psychiatric, counseling, eligibility

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.